Gefitinib (ZD1839)

目录号：S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1574.78	现货
100mg	RMB 1227.69	现货
250mg	RMB 2205.98	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献121篇：

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )
Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )
Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )
Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )
Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )
Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

特性

Gefitinib是有效的EGFR酪氨酸激酶抑制剂。

靶点

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

体外研究

Gefitinib 作用于高和低表达EGFR的细胞系，包括NR6, NR6M 和 NR6W 细胞系，有效抑制EGFR上全部酪氨酸磷酸化位点。磷酸化位点 Tyr1173和Tyr992敏感性较低，需要高浓度Gefitinib才能抑制。Gefitinib作用于NR6W细胞，高效阻断PLC-γ磷酸化, IC50为27nM。NR6wtEGFR 和NR6M细胞系具有低水平PLC-γ磷酸化， IC50 分别为 43 nM和 369 nM。Gefitinib抑制AKT磷酸化，作用于低EGFR和EGFRvIII表达的细胞系， IC50 分别为220 和263nM。Gefitinib按 0.1 到 0.5μM剂量处理，显著促进而不是废除 NR6M细胞形成集落。然而, 2μM Gefitinib 完全抑制 NR6M 集落形成。Gefitinib 作用于高和低EGFR表达的细胞系，EGF 刺激72小时后，快速抑制EGFR 和ERK 磷酸化，这种作用存在剂量依赖性。^[1]Gefitinib抑制 EGF驱动的未转化MCF10A 细胞生长，IC50为 20 nM。^[2] Gefitinib 作用于MDA-MB-231细胞，抑制EGF信号。Gefitinib严重抑制细胞数的增多，这种作用存在剂量依赖性。 ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	NXLxWI9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK4TWM2OD1yLkC1OEDPxE1?	M2fk[lE3PTF4NEez
NIH3T3	MWHGeY5kfGmxbjDBd5NigQ>?	Moe4NE4zKM7:TR?=	NXizZm13OiCq	MofESG1UVw>?	NVq0Uot4UW6qaXLpeIlwdiCxZjDFS2Yhe3SrbYXsZZRm\CCqdX3hckBmemKEMTDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCxOFQh\|ryP	M1[yXVE3PDhyMki0
COS7	MkLoSpVv[3Srb36gRZN{[Xl?	MXS5OkDPxE1?			NGrhTmxKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	NGfLVWIyPzF5OEeyNi=>
A549	M1LFW2N6fG:2b4jpZ{BCe3OjeR?=		Mly2PVYhcA>?	NFL3cnBFVVOR	M3Lid2lEPTB;MUOuOVkh\|ryP	M4K2[\|E5OzF\|OEC3
K562	NHPSUmtEgXSxdH;4bYMhSXO\|YYm=		MXG5OkBp	MUnEUXNQ	MULJR\|UxRTlwM{[g{txO	MkHpNVg{OTN6MEe=
MDA-MB-231	MYLDfZRwfG:6aXOgRZN{[Xl?		MUG5OkBp	MlfBSG1UVw>?	MlHZTWM2OD1\|Nj62NUDPxE1?	NG\STGUyQDNzM{iwOy=>
MOLT4	NUi3cZF[S3m2b4TvfIlkKEG\|c3H5		MoDYPVYhcA>?	NEfqdHpFVVOR	MUXJR\|UxRTF3LkCyJO69VQ>?	NIL4XmIyQDNzM{iwOy=>
MCF7	MWrDfZRwfG:6aXOgRZN{[Xl?	NEL1Tmk2OCEQvF2=	NVzqc4pGPzJiaB?=		MmHFTWM2OD1zMj6wOUDPxE1?	NXfKUmhXOTh5N{G4NVk>
BT474	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF;xZ\|Y4OiCq		NIqyVmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOFc1KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXSRoIzKHerdHigSWM2OCCxZjCwMlMh\|ryP	MWexPVAzQDR{NB?=
HN5	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlnvO\|IhcA>?		NYqwUFhjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkB4cXSqIFXDOVAhd2ZiMD6wNUDPxE1?	NVnMcFR6OTlyMki0NlQ>
BA/F3	NYTLR2RNS3m2b4TvfIlkKEG\|c3H5		MUO3NkBp		NEn6cVlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62IIfpeIghUUN3MDDv[kAxNjBzMEig{txO	MkjZNVkzOzl{Mkm=
NIH3T3	NFT2PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXHNUYMxPzJiaB?=		MkLRS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgUmlJNzOWMzDj[YxteyCneIDy[ZN{cW6pIHXyRlIh\2WwZTD3bZRpKEmFNUCgc4YhOC53NDFOwG0>	NHrhXXkyQTZ4NUO3Oy=>
MCF7 MX	MkjPSpVv[3Srb36gRZN{[Xl?		NFTyUFk{OCCvaX6=		MnXNTY5pcWKrdHnvckBw\iCEQ2LQJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?	M3XKWlE6QTN{OU[w
A431	NULFSoZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[xNEDPxE1?	Mlj2O\|IhcA>?		NXTqWmR3T0l3ME2wMlUyPCEQvF2=	NUfjXpFMOTl7Nkm0OlU>
A431	NHnkfmJMcW6jc3WgRZN{[Xl?	MYmwMlEh\|ryP	MYKxJIg>		NVHmWHpFUW6qaXLpeIlwdiCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdg>?	M{PMO\|E6QTZ7NE[1
A431	MYjLbY5ie2ViQYPzZZk>	NI\GOpEyODBizszN	NYHZb2NwOTBibXnu		M2SwVHBzd2yxbnfl[EBqdmirYnn0c5J6KGGldHn2bZR6KG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	MU[xPVk3QTR4NR?=
Sf9	NWXqflJUU2mwYYPlJGF{e2G7		MkTBNVAhdWmw	MmS5SG1UVw>?	NHfyN4tKdmirYnn0bY9vKG:oIFXHSnIh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemWlZYD0c5Ih[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzNizszN	MWKyNFA2PjR{NR?=
NCI-H1975	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIT1[HI2KM7:TR?=	NYezdpFCPzJiaB?=		NFnEUIVKSzVyPUiuNlYh\|ryP	NVLLXFBOOjBzNUG2O\|A>
NCI-H1975	MmLyT4lv[XOnIFHzd4F6	MXuxNEDPxE1?			NUXhXnpzUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NHLDe3EzODF3MU[3NC=>
NCI-H1975	MU\GeY5kfGmxbjDBd5NigQ>?	NUi1O2pjOTBizszN			MofyTY5pcWKrdHnvckBw\iCHUlLCNkBifXSxcHjvd5Bpd3K7bHH0bY9v	MWCyNFE2OTZ5MB?=
NCI-H1975	Mlr4SpVv[3Srb36gRZN{[Xl?	NWfC[HpjPSEQvF2=	NFLRfpE1QCCq		M1TjNGlv\HWldHnvckBw\iCjcH;weI9{cXNiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iClYYPwZZNmNTN?	NYf5WZp2OjBzNUG2O\|A>
A375	NIrCb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnPSOFghcA>?		MkDITWM2OD1{MD61OUDPxE1?	NF\xU5QzODNyNEWzOy=>
SMMC7721	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoLkOFghcA>?		NIHQc2tKSzVyPUOzMlEzKM7:TR?=	NWTTWppLOjB\|MES1N\|c>
DU145	NUnRTZd7S3m2b4TvfIlkKEG\|c3H5		MoHyOUBl	MVPEUXNQ	NWe2TGhMUUN3ME20Nk4yPyEQvF2=	Mn23NlA1PjZ3NUW=
MIAPaCa2	M2fEe2N6fG:2b4jpZ{BCe3OjeR?=		MYe1JIQ>	NFrFR5VFVVOR	M1fDVmlEPTB;NUCuOlIh\|ryP	M3PhTlIxPDZ4NUW1
PANC1	MnXUR5l1d3SxeHnjJGF{e2G7		M1PsdlUh\A>?	NY\K[2Z6TE2VTx?=	MUTJR\|UxRTRyLkSyJO69VQ>?	NVv6T5hoOjB2Nk[1OVU>
PC9	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDFS2ZTNWSnZnnjbYVvfCCqdX3hckBRSzliY3XscJMhf2m2aDDFR\|UxKG:oIECuNFE4KM7:TR?=	NW\FO\|BEOjF{MEi4NFI>
PC9	Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDndo94fGhvcnXzbZN1[W62IHj1cYFvKFCFOTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTTd2Nm;BO\|UxN1R5OUDNJI12fGGwdDD3bZRpKEWFNUCgc4YhPyEQvF2=	M{\ybFIyOjB6OECy
PC3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\lNVAh\|ryP	NH\wPJY4OiCq	MUHEUXNQ	NV3NW4VNUUN3ME23MlQh\|ryP	MWKyNVM2OzV2Nh?=
MDA-MB-468	NUHJUGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUSxdGhHOTByIN88US=>	M4O0UFQ5KGh?	NVLDNZh5TE2VTx?=	MmXPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdIm=	NVnUXXBiOjF2Mkm2N\|I>
Plasmodium falciparum					MWjxTHRUKHC{b3\pcIlv\yCob4KgbY5pcWKrdH;yd{Bw\iCSbHHzcY9lcXWvIH\hcINqeGG{dX2gdJJwdGmoZYLheIlwdg>?	M{PaVFIyQDF5MES1
NCI-H1993	NFzJboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4Pa[\|czKGh?	MULEUXNQ	M{iw[WlEPTB;MD6xJO69VQ>?	M3ruTFIyQTF4NEOz
NCI-H292	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3[3blczKGh?	NWXXbIZoTE2VTx?=	M3nwS2lEPTB;MD6wNkDPxE1?	MomwNlE6OTZ2M{O=
A431	NFjm[YhMcW6jc3WgRZN{[Xl?		M2W5SlIhcA>?	NVzTbYl2TE2VTx?=	NUjYPIxQUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCHR1[td5RqdXWuYYTl[EBpfW2jbjDBOFMyKHerdHigTWM2OCCxZjCwMlAxOSEQvF2=	NHfYNo8zOjFyMUGzNi=>
MCF7	M2jkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUWyPFZ5OTBywrFOwIcwdUx?	MWS0PEBp	MVfEUXNQ	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjDn[Y5mKHerdHigTWM2OCCxZjCxNk4xPSEQvF2=	NEC0cpUzOjFzOUGzNC=>
BT474	MVXDfZRwfG:6aXOgRZN{[Xl?	MX6xNEDPxE1?	M2HQR\|Q5KGh?		NGXHNXVEgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIFLUOFc1KGOnbHzz	MY[yNlE{QDNyOB?=
MCF7	M{SxdWN6fG:2b4jpZ{BCe3OjeR?=	M2nOWlExKM7:TR?=	Mmf1OFghcA>?		M37XXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iTVPGO{Bk\WyuczDveoVzNWW6cILld5NqdmdiRYLiRlIh[2WubIO=	NWDxemt5OjJzM{izNFg>
HCC827	NV63NmlPU2mwYYPlJGF{e2G7	Mn:wNE4yOjVizszN	M3vmXlI1KGh?	M3qzN2ROW09?	MXzJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQhYTFyNkigZZV1d3Cqb4PwbI9zgWyjdHnvci=>	MoT2NlI{Ozl\|NEK=
HCC827	M3\mSGtqdmG\|ZTDBd5NigQ>?	NInUTJoxNjF{NTFOwG0>	M{fEblI1KGh?	NUCyd5hDTE2VTx?=	MYDJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhTXKtIIDoc5NxcG:{eXzheIlwdg>?	NWLVT\|F7OjJ\|M{mzOFI>
HCC827	MXjLbY5ie2ViQYPzZZk>	NVzOe3ZWOC5zMkWg{txO	MoTYNlQhcA>?	NIXzZWdFVVOR	NH:xemZKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	NV;BUXQ{OjJ\|M{mzOFI>
A431	NX3lRVF6U2mwYYPlJGF{e2G7	NFfZ[IUyODBizszN	M4mxU\|MxKG2rbh?=		MkXHTY5pcWKrdHnvckBw\iCHR1\SJIRmemm4ZXSg[pJwdSCqdX3hckBCPDNzIHPlcIwhdWWvYoLhcoUh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7LVfseU1VgXJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxMlA5KM7:TR?=	MV[yNlY6QDd6Mh?=
H460	NY\z[JBCS3m2b4TvfIlkKEG\|c3H5		M3e5UlczKGh?		NGPtXnZKSzVyPUWuOVkh\|ryP	MYGyNlczPzR2OR?=
HT-29	MV;DfZRwfG:6aXOgRZN{[Xl?		MmfRO\|IhcA>?		NVjORnJUUUN3ME2zMlM3KM7:TR?=	MkTLNlI4Ojd2NEm=
SGC7901	NELxVmtEgXSxdH;4bYMhSXO\|YYm=		MX[3NkBp		MlXkTWM2OD1zMD6yOkDPxE1?	M3vOeVIzPzJ5NES5
A498	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEm4JINmdGy\|IHX4dJJme3OrbnegSWdHWiCjbnSgV3JEKHerdHigTWM2OCCxZjC4MlYh\|ryP	NG[3ZVczOjhzOEi0PC=>
Calu3	MVLDfZRwfG:6aXOgRZN{[Xl?	MVWxNEDPxGdxbVy=	NGTwflg4OiCq		MYDJR\|UxRTFwNjFOwG0>	MVqyN\|EyPjF4OB?=
FADU	Mn75R5l1d3SxeHnjJGF{e2G7	M4DoTFExKM7:Zz;tUC=>	MmHVO\|IhcA>?		MW\JR\|UxRTBwMEWg{txO	NXfLUYlpOjNzMU[xOlg>
HCC827	NUHPWmViS3m2b4TvfIlkKEG\|c3H5	NHnacpgyOCEQvHevcWw>	MUC3NkBp		MlPQTWM2OD1yLkCwNVUh\|ryP	NI\6W\|gzOzFzNkG2PC=>
PC9	NYe5d\|RST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVKxNEDPxGdxbVy=	NEfseWo4OiCq		MYfJR\|UxRTBwMEG0JO69VQ>?	M{XKPVI{OTF4MU[4
Sf9	NFvEbFRMcW6jc3WgRZN{[Xl?		NWr4XWpOOSCq	Mn65SG1UVw>?	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGdUXC22YXfn[YQhTUeIUjDMPFM1WiCvdYThcpQh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlAyPSEQvF2=	MY[yN\|YyOTZ7MR?=
16HBE14o-	NF:zRmtEgXSxdH;4bYMhSXO\|YYm=	MnfsNVAh\|ryP	NEK2ZWE4OiCq	NH7LW3RFVVOR	MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>	NYLhRY9iOjN4Nki0OFE>
NCI-H1975	NEjkR5ZEgXSxdH;4bYMhSXO\|YYm=	NIHxN4cyOCEQvF2=	M1LkZ\|czKGh?	M4jqVWROW09?	NIrOR3REgXSxdH;4bYNqfHliYXfhbY5{fCCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB4LkmxO{DPxE1?	MkXBNlM3Pjh2NEG=
16HBE	NFPXOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkPpO\|IhcA>?	NUfnR\|VwTE2VTx?=	NG\mT2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKge4l1cCCLQ{WwJI9nKDFwNkCxJO69VQ>?	M2XHVFI{Pzl{M{G4
16HBE	M37uNmZ2dmO2aX;uJGF{e2G7	MWmxNFAh\|ryP	NH7ZTFUyPTBibXnu	NHHlVI1FVVOR	NVvkWWw{UW6mdXP0bY9vKG:oIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKGmwIHj1cYFvKDF4SFLFJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGVITlJ?	NVP0SG5HOjN5OUKzNVg>
A549	NXz5cFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1mxVFczKGh?	M{DoWGROW09?	MmHmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh\|ryP	MlnhNlM4QTJ\|MUi=
SH-SY5Y	MmXtR5l1d3SxeHnjJGF{e2G7		NGLhSW44OiCq		M3zEemlEPTB;MUiuNlEh\|ryP	NXHXc4xGOjN6N{G5NFk>
LoVo	Mk\0T4lv[XOnIFHzd4F6		MUSyJEBp	NYrTbmk5TE2VTx?=	M{XvZmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwME[yJO69VQ>?	Ml[5NlM6OzB7OUS=
PC9	NUnQXXRZU2mwYYPlJGF{e2G7		NEDlelkzKGh?	MlvPSG1UVw>?	M4nO[mlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEC4O{DPxE1?	MUmyN\|k{ODl7NB?=
HCC827	Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV\CUJp{PzJiaB?=		MVnJR\|UxRTBwMEGyJO69VQ>?	MVSyN\|k4OzF4OB?=
A549	MXPLbY5ie2ViQYPzZZk>	NHLqWGwyKM7:TR?=	M4jW[lEhcA>?	NEXYTpRFVVOR	NHPofnJKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzl7IN88US=>	MnPHNlM6QDh\|NUS=
A549	MYPGeY5kfGmxbjDBd5NigQ>?	MWWxJO69VQ>?	NXrq[VNOOSCq	MmXISG1UVw>?	NES1SW5E\WyudXzhdkB2eHSja3W=	M1zKUFI{QTh6M{W0
HCC827	NHi2SIRMcW6jc3WgRZN{[Xl?	M3vB[\|AvPSEQvF2=	NXX2T5ZlOiCq	MUnEUXNQ	NVzFeG1lUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=	NFjTSGwzOzl7M{OyPC=>
HCC827	M13xcmZ2dmO2aX;uJGF{e2G7	NX\nR5pMOC53IN88US=>	M1n5RlIhcA>?	NGfwdGdFVVOR	NVLCd\|lDUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=	NWXD[pRIOjN7OUOzNlg>
HCC827	NVLIRpFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF63epgyOCEQvF2=	MVG3NkBp	NG\zbWRFVVOR	NFH4S49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIdm\mm2aX7pZk1{\W6\|aYTpeoUhcHWvYX6gTGNEQDJ5IHPlcIx{KGijcnLvdolv\yCHR1\SJGU4PDZidH:gRVc2OCCmZXzleIlwdiC5aYToJGlEPTBib3[gNE4xODV6MTFOwG0>	MWWyOFA2OzZ5NB?=
A431	NGfnXoxMcW6jc3WgRZN{[Xl?	MnfzNVAxKM7:TR?=	MWqzNEBucW5?		M4fsRWlvcGmkaYTpc44hd2ZiRVfGVkBqdiC\|aHXkJI1mdWK{YX7lJJZme2mlbHXzJJdqfGhiSVO1NEBw\iBzLkGg{txO	NHSzWmEzPDB7NESzNi=>
BCRP-MDCK2	Mnu0SpVv[3Srb36gRZN{[Xl?	M3HaS\|EvQCEQvF2=	M4T5Z\|czKGh?	MXvEUXNQ	NGH4ZlVKdmO{ZXHz[UBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	NULINnMzOjRzOESyNVM>
BCRP-MDCK2	NGf2OolHfW6ldHnvckBCe3OjeR?=	Ml;mNU45KM7:TR?=	Mlv1O\|IhcA>?	M3jYPWROW09?	MVLS[YR2[3Srb36gc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	NHznelkzPDF6NEKxNy=>
MDCK	M2XOS2N6fG:2b4jpZ{BCe3OjeR?=		NH3JXVA4OiCq	NFnnOZZFVVOR	M16zfGdKPTB;MT60OUDPxE1?	NGfpOGIzPDF6NEKxNy=>
MDCK2	NIe3WGhHfW6ldHnvckBCe3OjeR?=	NEHVVlgyNjhizszN	M1H6SlczKGh?	NGfsNWVFVVOR	NEXxcoVKdmirYnn0bY9vKG:oIHj1cYFvKEKFUmCg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KEixZXPod5QhOzN\|NEKgZYNkfW23bHH0bY9vKHerdHigTWM2OCCxZjCzMlE6KM7:TR?=	NIHo[4EzPDF6NEKxNy=>
A431	MnrqR5l1d3SxeHnjJGF{e2G7		M2fjNlczKGh?	MW\EUXNQ	MnrLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txO	MWqyOFQyOTF{Mx?=
Calu3	Mkn5R5l1d3SxeHnjJGF{e2G7		MU[3NkBp	MXnEUXNQ	M4T3ZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNidHV\|IHPlcIx{KGW6cILld5NqdmdiSFXSNkB4cXSqIFnDOVAhd2ZiMD65PUDPxE1?	NFj2c3AzPDRzMUGyNy=>
KB	MlvvT4lv[XOnIFHzd4F6	MUWxNEDPxE1?	NHXXbW0yKGh?	MnjCSG1UVw>?	MkmxTY5pcWKrdHnvckBw\iCHR1[td5RqdXWuYYTl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIFXHSnIhf2m2aDDJR\|UxKG:oIECuNFI2KM7:TR?=	M2fUTFI1PDFzMUKz
BEAS2B	M3fLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnvOVAh\|ryP	NWDXN2FKPzJiaB?=	Mlj6SG1UVw>?	NYTTeXBIUUN3ME2xN{46PCEQvF2=	MUiyOFYxPzV7MR?=
NCI-H1975	M2r6WWZ2dmO2aX;uJGF{e2G7	M1;Jb\|ExOCEQvF2=	MkH5NVUxKG2rbh?=	NGH5OnlFVVOR	M{i4dWlv\HWldHnvckBw\iCQTzDwdo9lfWO2aX;uJIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	M2jCR\|I1PjB5NUmx
Hela	NY\ORnFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkW5NlQhcA>?	NEjFVWlFVVOR	MWLJR\|UxRTJwNkeg{txO	MYKyOFc{OTJ6MR?=
HepG2	NYjsRpQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\1dlI1KGh?	NUm0R3NnTE2VTx?=	MmDBTWM2OD14LkSyJO69VQ>?	MWiyOFc{OTJ6MR?=
Sf9	Ml;vT4lv[XOnIFHzd4F6		M2ewZ\|ExKG2rbh?=	Mo\ESG1UVw>?	MYTJcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gdoVkd22kaX7hcpQhcGm\|LYTh[4dm\CCHR1\SJEhidWmwbzDhZ4llKDZ2NT2xNVg3MSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODJizszN	NHfH[GIzPDd\|MUK4NS=>
SW620	MWHDfZRwfG:6aXOgRZN{[Xl?		MVy0PEBp	MW\EUXNQ	MkDsTWM2OD1{OD6yJO69VQ>?	NYHOOXNqOjR7MEC1PVQ>
HCC827	NUHHR4ZDTnWwY4Tpc44hSXO\|YYm=	M3fKcFAvPSEQvF2=	NWHM[HJlOiCq	MYLEUXNQ	Mo[0[I9meyCwb4SgbY5pcWKrdDDjMW1mfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25?	NWXl[\|NYOjN7OUOzNlg>
HCC827	MW\GeY5kfGmxbjDBd5NigQ>?	MmXjNE42KM7:TR?=	NELWT\|EzKGh?	NImzO5RFVVOR	MnT2[I9meyCwb4SgbY5pcWKrdDDjMW1mfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB2ND:0NkBxcG:\|cHjvdplt[XSrb36=	MkLDNlM6QTN\|Mki=
HCC827	M4eydmN6fG:2b4jpZ{BCe3OjeR?=	Mn3rNE42KM7:TR?=	NWLpfGN5PzJiaB?=	MUjEUXNQ	MkjUbIF{KG6xIHP5eI91d3irY3n0fS=>	MXyyN\|k6OzN{OB?=
NCI-H1975	M{C4cmZ2dmO2aX;uJGF{e2G7	NUK2bpFZOTBizszN	M2jpdVghcA>?	MX3EUXNQ	NFnlOFNld2W\|IH7veEBqdmirYnn0bUBGT0[UIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:w	M4LxVVI{OTF4MU[4
A431	NEnRUnZMcW6jc3WgRZN{[Xl?	NFPGW4YyKM7:TR?=	MXKxJIg>	MVjEUXNQ	MnjabIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	NGHq[\|EzPDlyMEW5OC=>
LNCaP	MX;GeY5kfGmxbjDBd5NigQ>?	MV6xNEDPxE1?	NXvpcotPOmhib4KgOEBp	NYXhOVRtTE2VTx?=	NE\sVJVld2W\|IH7veEBqdmirYnn0JIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiaX3teY5weHW{aX\p[YQh\myjZz30ZYdo\WRiQn34JIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzN{UG3BWHA>	NWrTPGc6OTh4NkezNVI>
H1975	NFz6TpVMcW6jc3WgRZN{[Xl?	MojUNUDPxE1?	MoDENlQhcA>?	MonLSG1UVw>?	M2DHNoRw\XNibn;0JIlvcGmkaYSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	NHvPbZEzPDZyN{W5NS=>
H1975	NH7NdHdHfW6ldHnvckBCe3OjeR?=	M4jUXVEh\|ryP	MU[yOEBp	MmTMSG1UVw>?	M1HBfIRw\XNibn;0JIlvcGmkaYSgSXJMKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVQ>?	NFXpNJkzPDZyN{W5NS=>
HCC827	NGi3RohMcW6jc3WgRZN{[Xl?	NHXte4kxNjFzIN88US=>	MUOxJIg>	M3;kVWROW09?	MkLxbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XO\|ZYPz[YQh[XNicnXjc5Zmenlib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	NI\6PVQzPDF{NEi5PC=>
H1975	MV\LbY5ie2ViQYPzZZk>	NGDHNogxNjN\|IN88US=>	NY\SS3ZSOiCq	MlT2SG1UVw>?	MXTkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRWtVKHCqb4PwbI9zgWyjdHnvci=>	MoC0NlQyOjR6OUi=
H1975	MXTLbY5ie2ViQYPzZZk>	NEDqeHIxNjN\|IN88US=>	MofuNkBp	M1;DXWROW09?	NHvHZmxld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdg>?	MnH5NlQyOjR6OUi=
H1975	NV[4R2lKU2mwYYPlJGF{e2G7	MnLPNE4{OyEQvF2=	NUSwZZo4OiCq	NH;Dco9FVVOR	MmP3[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;u	NFL6Z2gzPDF{NEi5PC=>
H1975	MUjLbY5ie2ViQYPzZZk>	M3GxPFAvOTJ3IN88US=>	M4DoOFI1KGh?	MUHEUXNQ	M3ThWoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MnTKNlI{Ozl\|NEK=
H1975	NGnwbpZMcW6jc3WgRZN{[Xl?	M2HhbVAvPSEQvF2=	NXi3d3BGOjRiaB?=	NGDmTnRFVVOR	MVvkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEW{azDwbI9{eGixconsZZRqd25?	MWGyNlM{QTN2Mh?=
H1975	M175R2tqdmG\|ZTDBd5NigQ>?	MV6wMlUh\|ryP	Ml[5NlQhcA>?	MVzEUXNQ	MVPkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	NYLMRZZUOjJ\|M{mzOFI>
MIAPaCa2	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXKyMlUh\|ryP	NXjoS\|NsPzJiaB?=	NF:4TotFVVOR	NV;IfHBCcGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	MYKyNFQ3PjV3NR?=
MIAPaCa2	NFr6WYhEgXSxdH;4bYMhSXO\|YYm=	M4HqSVEh\|ryP	MY[xNEBl	NWrnRZpsTE2VTx?=	NI\VTXBp[XNibn:gZ5l1d3SxeHnjbZR6KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOxbH;ufUBnd3KvYYTpc44>	MWiyNFQ3PjV3NR?=
MIAPaCa2	NGXaRndCeG:ydH;zbZMhSXO\|YYm=	M3jWVFExKM7:TR?=	MWWyOIghd3JiNEigbC=>	NF7FdpBFVVOR	NHnXTVRld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	M1HXV\|IxPDZ4NUW1
MIAPaCa2	MnW2RZBweHSxc3nzJGF{e2G7	NWXDNZN7OjBizszN	MlfqNlQhcA>?	MXHEUXNQ	NGjlSVdld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KGOjc4Dhd4UhOyCjY4TpeoF1cW:w	NGLE[VIzODR4NkW1OS=>
EoL-1	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTuWmRKSzVyPUWuNVchdk1?	NIqwPVFUSU6JRWK=
NCI-H720	NV7UN\|hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTJ4LkmyJI5O	M3LIO3NCVkeHUh?=
NCI-SNU-5	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;SbG9GUUN3ME2yPE4yQSCwTR?=	MlLJV2FPT0WU
EW-3	M3rQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHQeJBKSzVyPUS2MlA1KG6P	NVPjTYx7W0GQR1XS
HCC2218	NHr0WVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjVTWM2OD13MD61PUBvVQ>?	NH6zUWxUSU6JRWK=
HuO-3N1	NYfFZ\|h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfFZotKSzVyPUW2MlA6KG6P	MUPTRW5ITVJ?
DB	NXvX[GZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHHTWM2OD14MD65OkBvVQ>?	NGjuOnlUSU6JRWK=
HSC-4	MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DieGlEPTB;NkGuOVMhdk1?	MXfTRW5ITVJ?
DOK	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPxTWM2OD17Mz62NkBvVQ>?	MmjPV2FPT0WU
H9	M4rmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoGxTWM2OD1zM{euNkBvVQ>?	Mn7VV2FPT0WU
NCI-H292	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTF4Mj62OkBvVQ>?	MXzTRW5ITVJ?
HSC-2	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;4ZWlKSzVyPUG2OU42PyCwTR?=	NGG5TIdUSU6JRWK=
LU-65	MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zt[GlEPTB;MU[2MlYyKG6P	MWfTRW5ITVJ?
BV-173	NGLFPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfJTWM2OD1zOE[uOVUhdk1?	NVy3W\|l6W0GQR1XS
LB2241-RCC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorHTWM2OD1zOUSuPVMhdk1?	NIG5cFhUSU6JRWK=
KG-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTJyND6zOEBvVQ>?	NUPPUXFbW0GQR1XS
CHL-1	M3PKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYP3NHB1UUN3ME2yNFgvPTFibl2=	NH[0TpZUSU6JRWK=
KYSE-140	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrnTWM2OD1{MEmuPVYhdk1?	MX7TRW5ITVJ?
DU-145	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnuxTWM2OD1{MUmuNFQhdk1?	NXW0UWxzW0GQR1XS
EW-13	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\zOWFKSzVyPUKyOU4yKG6P	M13iS3NCVkeHUh?=
KYSE-450	NYG4Z\|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfLUGxKUUN3ME2yOFcvQTJibl2=	Mk\NV2FPT0WU
CAL-72	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfRV45KSzVyPUK2PE44OyCwTR?=	M1TUS3NCVkeHUh?=
MEG-01	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTJ5Nj63OkBvVQ>?	NXPCUJVHW0GQR1XS
HCE-T	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLFbZRKSzVyPUK3PU44QSCwTR?=	Mn7kV2FPT0WU
NCI-SNU-1	NEH0fGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnpOoZKSzVyPUK4N{4{OiCwTR?=	NVv1WmxOW0GQR1XS
CAL-27	NYnmfHVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzjU4xnUUN3ME2yPFkvODhibl2=	MULTRW5ITVJ?
BALL-1	M2rFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3pUm5KSzVyPUK5O{41OiCwTR?=	NInuW\|hUSU6JRWK=
SBC-1	NXvlU2IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTNyNz63PUBvVQ>?	Mor4V2FPT0WU
CAL-54	M1\OS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTjb3pGUUN3ME2zNVEvOjNibl2=	NWjke\|VCW0GQR1XS
TI-73	NYfRSppGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3pTWM2OD1\|MUKuO\|Uhdk1?	MWXTRW5ITVJ?
P12-ICHIKAWA	M2Hzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfzOmtKSzVyPUOyPE4xPiCwTR?=	MoTDV2FPT0WU
ACHN	NHLiTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7NWmNKSzVyPUOzNU41KG6P	M3vvXHNCVkeHUh?=
PC-14	NH\VVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfCcIZJUUN3ME2zN\|MvPDFibl2=	MXnTRW5ITVJ?
HCC1806	NHHHPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;vTWM2OD1\|M{euOVEhdk1?	MonIV2FPT0WU
SK-MEL-24	M4XVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLoeIN6UUN3ME2zN\|cvQDdibl2=	M3zBWHNCVkeHUh?=
A4-Fuk	M{mzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTN3MD6wNkBvVQ>?	Mni0V2FPT0WU
ECC10	NIHjTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUD4TFhiUUN3ME2zOVIvQTZibl2=	NU\3dlh3W0GQR1XS
KASUMI-1	NXfEVlFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPWR4dKSzVyPUO2Ok44OyCwTR?=	MUfTRW5ITVJ?
CAL-33	M2rtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTN5MD65JI5O	Mny2V2FPT0WU
MDA-MB-175-VII	NGj5blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS5TWM2OD1\|N{iuPFghdk1?	NGT4OGVUSU6JRWK=
NUGC-3	NFfGeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjPTWM2OD12MEGuPFEhdk1?	MULTRW5ITVJ?
KY821	M2HCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7sUnlKSzVyPUSwPE42PyCwTR?=	MVnTRW5ITVJ?
CTB-1	NFT6TYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTR{ND60JI5O	NHLWSmlUSU6JRWK=
DoTc2-4510	NUXBNnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfyeZNpUUN3ME20OFIvOTJibl2=	MnfnV2FPT0WU
EFO-27	M{XqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfxR4RzUUN3ME20OVQvPzRibl2=	MmPQV2FPT0WU
BPH-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PTd2lEPTB;NEmxMlE3KG6P	MVnTRW5ITVJ?
KYSE-270	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXDfYVKSzVyPUS5PE43PSCwTR?=	MXHTRW5ITVJ?
HO-1-N-1	MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzJTWM2OD13MEmuNlUhdk1?	NYHZOZE5W0GQR1XS
SK-MEL-1	M1L0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TGU2lEPTB;NUGwMlk6KG6P	M2WzbXNCVkeHUh?=
MOLT-13	NIPqc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK1O2V1UUN3ME21NVQvQDJibl2=	M4[xUHNCVkeHUh?=
TK10	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnq[5RKSzVyPUWxOU4yOSCwTR?=	NEfwXIRUSU6JRWK=
HN	M3fjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTVzNz6zPEBvVQ>?	M1zzPXNCVkeHUh?=
SCC-15	M1;memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvhPZlGUUN3ME21NlUvPjhibl2=	M1n5bHNCVkeHUh?=
NCI-H358	NWTSTFA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzUTWM2OD13MkeuOlYhdk1?	NEL2eHdUSU6JRWK=
KYSE-180	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml[xTWM2OD13M{CuOlIhdk1?	NW\5doxKW0GQR1XS
NCI-H82	M4GxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTV2MD61JI5O	MVjTRW5ITVJ?
NB7	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\HTWM2OD13NE[uN\|Ihdk1?	NF7DcmtUSU6JRWK=
DSH1	NFLldFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTV4Nj64PEBvVQ>?	M3iwcXNCVkeHUh?=
RS4-11	NYjIdoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTV4OD61PUBvVQ>?	MV3TRW5ITVJ?
CAN	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUG1XllbUUN3ME21PFAvPzZibl2=	M{LK[3NCVkeHUh?=
Ca9-22	NVGyVWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLvcY0{UUN3ME21PFgvPjRibl2=	NFTxRVdUSU6JRWK=
CAL-39	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\Le4ZKSzVyPUW5Ok4{KG6P	NFrpXIpUSU6JRWK=
NCI-H1623	M2LuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTV7OT6zOkBvVQ>?	NVuyNIM5W0GQR1XS
FADU	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTZyND62PUBvVQ>?	NWrsTIFtW0GQR1XS
NB69	M{HuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFq4OWtKSzVyPU[xOE4{PSCwTR?=	M2PwSnNCVkeHUh?=
Ramos-2G6-4C10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnf4TWM2OD14MkGuOFYhdk1?	MmrXV2FPT0WU
LB1047-RCC	NGTOVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3q4SWlEPTB;NkK1MlI6KG6P	NFiwW3RUSU6JRWK=
MV-4-11	M1mxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz1TWM2OD14MkeuO{BvVQ>?	MlXlV2FPT0WU
DBTRG-05MG	M{HwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYWwSotMUUN3ME22N\|IvOjhibl2=	NX;EVZV6W0GQR1XS
ME-180	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTZ\|Mj65JI5O	MUPTRW5ITVJ?
NBsusSR	NELnbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHYXVhMUUN3ME22OFYvPTJibl2=	NVjrTWdvW0GQR1XS
COR-L105	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXPTWM2OD14NkKuOVMhdk1?	M2XQT3NCVkeHUh?=
ETK-1	NHHJTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFj2boZKSzVyPU[2Nk42QSCwTR?=	MYPTRW5ITVJ?
L-363	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHe4e45KSzVyPU[3NU46PCCwTR?=	M37ZbnNCVkeHUh?=
LU-134-A	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjkUY06UUN3ME23NVkvODlibl2=	NWfqe\|RUW0GQR1XS
NCI-H1770	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDiTWM2OD15MkKuOEBvVQ>?	MUjTRW5ITVJ?
HAL-01	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTd\|ND63NUBvVQ>?	M1TSTXNCVkeHUh?=
COLO-684	M{jKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHGUWdKSzVyPUe1N{4xOSCwTR?=	NYe2[pd{W0GQR1XS
TE-6	NVXxRY03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfqTWM2OD15NkSuN\|Ehdk1?	M2TDU3NCVkeHUh?=
A431	M135T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTlXZRKSzVyPUe4NE4xPCCwTR?=	M3nuU3NCVkeHUh?=
LU-135	NFzTT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojpTWM2OD15OEOuNFMhdk1?	MljuV2FPT0WU
EC-GI-10	M{DT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDhSodKSzVyPUe4PE42OiCwTR?=	NWDU[XEyW0GQR1XS
TE-12	MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTh{MT6xNUBvVQ>?	M4rxeXNCVkeHUh?=
LoVo	NH62V\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MomzTWM2OD16NUmuNFYhdk1?	MXrTRW5ITVJ?
23132-87	NEXVc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnDNFhMUUN3ME24OlQvOjhibl2=	NV\XepRvW0GQR1XS
AU565	M{i2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTh4OT62JI5O	MkiyV2FPT0WU
DEL	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLQNG5bUUN3ME24O\|cvPjVibl2=	M1zJNHNCVkeHUh?=
COR-L88	M3q0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPXZZpKSzVyPUi4Nk4zPiCwTR?=	MVPTRW5ITVJ?
NCI-H2126	NET3OIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XPOmlEPTB;OEiyMlg{KG6P	NFfXOVRUSU6JRWK=
CAPAN-1	NHTmS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfBe29KSzVyPUi4N{4zQSCwTR?=	M4j5NHNCVkeHUh?=
BT-474	NE\wTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTl\|OD6xOEBvVQ>?	NHrOV3RUSU6JRWK=
BHY	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\L[FJxUUN3ME25O\|UvPDhibl2=	MVrTRW5ITVJ?
HT-3	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfhTHk1UUN3ME25PFIvPDFibl2=	Ml\DV2FPT0WU
SK-NEP-1	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rM[2lEPTB;OUi5MlQ1KG6P	MVrTRW5ITVJ?
MS-1	NUm2OYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfFRo1pUUN3ME25PVQvPjlibl2=	M4PWZXNCVkeHUh?=
DOHH-2	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HvbWlEPTB;MT6wNFAzOSEQvF2=	M13MPXNCVkeHUh?=
NCI-H1304	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYOyOZdvUUN3ME2xMlAyPjR\|IN88US=>	NULnTXNqW0GQR1XS
EM-2	NU\aTHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzJeVZLUUN3ME2xMlA{ODF4IN88US=>	M1TNdXNCVkeHUh?=
MHH-PREB-1	NF:4ZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXlWmJKSzVyPUGuNFg1PTFizszN	M4m3S3NCVkeHUh?=
KU-19-19	NYLWfGdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7i[YtpUUN3ME2xMlA5PTRzIN88US=>	NVTkOXJ{W0GQR1XS
NCI-H1648	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37oZWlEPTB;MT6xNFYyPiEQvF2=	NXH3eFltW0GQR1XS
MKN1	NFLEeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHGUlB6UUN3ME2xMlIyQTh5IN88US=>	M1\YbnNCVkeHUh?=
SNU-449	M3\DdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jx[mlEPTB;MT6yNlIxQCEQvF2=	NWTWe4lrW0GQR1XS
OAW-42	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\0TWM2OD1zLkK3PFI2KM7:TR?=	NWjuVJlUW0GQR1XS
769-P	M3jKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HFcGlEPTB;MT6yO\|kyQCEQvF2=	NWLCd4FXW0GQR1XS
SW1088	NF\LcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPkb2lKSzVyPUGuNlk3ODdizszN	M{P0V3NCVkeHUh?=
GCIY	M{jpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFwM{CxN\|Ih\|ryP	NWDrRpZDW0GQR1XS
CTV-1	NYDDRY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPGToJKSzVyPUGuN\|A5KM7:TR?=	M1TobXNCVkeHUh?=
NCI-H1092	MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3GTWM2OD1zLkOwPFUh\|ryP	MlXyV2FPT0WU
NKM-1	Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnrTWM2OD1zLkOyOVk4KM7:TR?=	NGnNZWxUSU6JRWK=
NCI-H1650	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFW2SWpKSzVyPUGuN\|M1QDJizszN	M3X4cXNCVkeHUh?=
SW954	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLWbZVKSzVyPUGuN\|QxPDhizszN	MYTTRW5ITVJ?
SW48	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELnc3ZKSzVyPUGuN\|Y3OThizszN	M3zyeXNCVkeHUh?=
SK-N-DZ	NGPXSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEiybZlKSzVyPUGuN\|Y6PDdizszN	MXrTRW5ITVJ?
KMOE-2	M2rPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTZTWM2OD1zLkO5PFE2KM7:TR?=	NWfkWW84W0GQR1XS
NB5	NFzmU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzwZYl4UUN3ME2xMlQxQDl2IN88US=>	MX\TRW5ITVJ?
CCRF-CEM	NV\5[nFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvnT4lKSzVyPUGuOFEyOSEQvF2=	NXv5U4VCW0GQR1XS
RH-1	NEfjbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3OSWxKSzVyPUGuOFEyOzZizszN	M4\nOXNCVkeHUh?=
NCI-H526	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTFwNEO4NlYh\|ryP	MnjjV2FPT0WU
697	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTFwNESxNFQh\|ryP	NGPYN3FUSU6JRWK=
J82	M{XDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjhTWM2OD1zLkS1O\|Y3KM7:TR?=	MlWwV2FPT0WU
BE-13	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTFwNUC2O\|Eh\|ryP	MlPvV2FPT0WU
SAS	M3jXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTtTWM2OD1zLkWxOlIzKM7:TR?=	NHH5SYtUSU6JRWK=
SCC-25	NXvI[\|hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjLW5h2UUN3ME2xMlUzOzJ{IN88US=>	M{i1fnNCVkeHUh?=
LAMA-84	M2LxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TOfmlEPTB;MT61N\|gyPSEQvF2=	NV\MT3NFW0GQR1XS
HSC-3	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTFwNUSzPEDPxE1?	MWLTRW5ITVJ?
BT-549	NFLVO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTFwNUi3OFch\|ryP	MlqwV2FPT0WU
ML-2	NW\YRlZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTRT3R2UUN3ME2xMlY1ODJ7IN88US=>	M3\YeHNCVkeHUh?=
BB30-HNC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TNTWlEPTB;MT62PFk4OiEQvF2=	MUXTRW5ITVJ?
PANC-03-27	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;nTWM2OD1zLkewNVM6KM7:TR?=	MoPrV2FPT0WU
COLO-678	M3nlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGD3fXFKSzVyPUGuO\|M1PDRizszN	NFntWXlUSU6JRWK=
NCI-H1666	NIPUPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvhTWM2OD1zLke0O\|A1KM7:TR?=	MYXTRW5ITVJ?
NCI-H209	M{G1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DyV2lEPTB;MT63O\|I3QSEQvF2=	MnywV2FPT0WU
EPLC-272H	NGrJe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfweItKSzVyPUGuPFU2PDlizszN	NHPWWmtUSU6JRWK=
OMC-1	NUPXb29pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFwOUm4PFgh\|ryP	MXXTRW5ITVJ?
HCC70	M4rNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJwMEC4NVUh\|ryP	MkC1V2FPT0WU
CAL-12T	NEnt[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTJwMEG4OlEh\|ryP	Mm\vV2FPT0WU
TGBC24TKB	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3H0V2lEPTB;Mj6wNlk3OSEQvF2=	NXnVcYdEW0GQR1XS
EKVX	NEW1XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTJwMES5N\|kh\|ryP	MYDTRW5ITVJ?
SW1116	NXTpSYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUD2S5Z3UUN3ME2yMlA3ODB7IN88US=>	MVXTRW5ITVJ?
NCI-H2009	NUXnU\|U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3GTWM2OD1{LkC2NlE1KM7:TR?=	MnfGV2FPT0WU
RPMI-8866	M3fDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwMEi0PFEh\|ryP	MkjXV2FPT0WU
KARPAS-45	M{nPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJwMUK0O\|kh\|ryP	MVTTRW5ITVJ?
RXF393	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXURYNUUUN3ME2yMlE{ODN4IN88US=>	NEHXWHhUSU6JRWK=
786-0	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\5OWhKSzVyPUKuNVg1ODZizszN	M2\tWHNCVkeHUh?=
SCC-4	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVG4XFZmUUN3ME2yMlIyPzd4IN88US=>	M4jUc3NCVkeHUh?=
BT-20	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4iyOmlEPTB;Mj6yOlc1PCEQvF2=	MU\TRW5ITVJ?
A498	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEizW5ZKSzVyPUKuNlk1OTVizszN	NE\KUnpUSU6JRWK=
IGROV-1	M{jDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTaTWM2OD1{LkOxNlM4KM7:TR?=	MUDTRW5ITVJ?
JVM-3	NUm0ZWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33mc2lEPTB;Mj6zOFY1OyEQvF2=	MWPTRW5ITVJ?
NCI-H2170	NVvCVmdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3aTWM2OD1{LkO0O\|g{KM7:TR?=	MmDBV2FPT0WU
EW-18	NFu3cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLCT\|FKSzVyPUKuN\|U1PzFizszN	NXP3ZVNsW0GQR1XS
KU812	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\HZVlKSzVyPUKuN\|Y4PzlizszN	MWTTRW5ITVJ?
NY	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33jV2lEPTB;Mj6zO\|I4KM7:TR?=	M1P3N3NCVkeHUh?=
HTC-C3	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;pZmlEPTB;Mj60NlI3PyEQvF2=	MWLTRW5ITVJ?
CFPAC-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7RTWM2OD1{LkSzPFY1KM7:TR?=	NUe2bZVjW0GQR1XS
HH	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHvZnVKSzVyPUKuOFk5PTRizszN	MYLTRW5ITVJ?
MKN7	NHL3WVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;OTWM2OD1{Lk[yO\|Q5KM7:TR?=	NF\3UndUSU6JRWK=
TE-8	NUTLS4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1T0cmlEPTB;Mj62N\|Y2OyEQvF2=	NWL2Xmh5W0GQR1XS
MC-IXC	NEPjU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVT0Wod6UUN3ME2yMlY1PDV\|IN88US=>	NF7mWoFUSU6JRWK=
DMS-79	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\LOZhrUUN3ME2yMlY6Ojh2IN88US=>	NWOyZ4d{W0GQR1XS
Detroit562	NUHjfXF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPC[3JVUUN3ME2yMlY6QDR3IN88US=>	NEW0cFRUSU6JRWK=
HuP-T4	NW\PbZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTJwN{K4NVgh\|ryP	NVe2bWxNW0GQR1XS
QIMR-WIL	NFTpR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MleyTWM2OD1{Lke1PVUzKM7:TR?=	NIjMepNUSU6JRWK=
BB65-RCC	M3TCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDWfpNKSzVyPUKuPFA4OTNizszN	NIXFZ4hUSU6JRWK=
PC-3	M2fvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjyTWM2OD1{LkizN\|E4KM7:TR?=	NYXYRmhwW0GQR1XS
OVCAR-3	M1rh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3[xN2lEPTB;Mj64OVU6PCEQvF2=	MojqV2FPT0WU
KYSE-510	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTJwOE[3PFYh\|ryP	NEHIc5VUSU6JRWK=
HC-1	M3PtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37YbGlEPTB;Mj65OFAyOiEQvF2=	NHPXcnRUSU6JRWK=
NCI-H1693	NHfpZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTJwOUW4PVch\|ryP	NX7tXGc3W0GQR1XS
DU-4475	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknqTWM2OD1{Lkm5NFUzKM7:TR?=	MVLTRW5ITVJ?
COLO-680N	M1fDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTNwMEC0PVUh\|ryP	NFHJfodUSU6JRWK=
MN-60	NHPUNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DtdGlEPTB;Mz6wOFk4PCEQvF2=	NWDmcW5iW0GQR1XS
BCPAP	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTNwMEiyPVUh\|ryP	MX3TRW5ITVJ?
647-V	NFrjfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTNwMU[yNkDPxE1?	Ml\FV2FPT0WU
HT-1376	NHTXc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjsSHU3UUN3ME2zMlIxPTB4IN88US=>	NH\aZWlUSU6JRWK=
NCI-H1793	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjBcFdKSzVyPUOuNlExQThizszN	NIXqUY1USU6JRWK=
SW1463	NFn0NGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHrXJVKSzVyPUOuNlYyQTJizszN	M4Lrb3NCVkeHUh?=
NCI-H727	NYTnUY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HEW2lEPTB;Mz6zPFU5PCEQvF2=	NIX5XG9USU6JRWK=
LB771-HNC	M3zrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljuTWM2OD1\|LkO5NVI3KM7:TR?=	MU\TRW5ITVJ?
D-542MG	NEPYZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLGO2VKSzVyPUOuOFQzOjJizszN	NX\iXZhOW0GQR1XS
NTERA-S-cl-D1	MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTNwNES5OVch\|ryP	NHGy[JRUSU6JRWK=
C8166	M4jPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\JTWM2OD1\|LkS2OVIyKM7:TR?=	NUTLT4E{W0GQR1XS
639-V	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDjSW5sUUN3ME2zMlU4Pzl{IN88US=>	M{DVPHNCVkeHUh?=
TE-1	NYDZPYtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjRNGhKSzVyPUOuOVkyPjlizszN	MX7TRW5ITVJ?
OAW-28	NF[0W3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3wS\|ZKSzVyPUOuOVk1OjZizszN	M13vUnNCVkeHUh?=
SK-LU-1	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXuUnI{UUN3ME2zMlYxPjR3IN88US=>	M4HqXHNCVkeHUh?=
CaR-1	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrLd2R4UUN3ME2zMlYyODR6IN88US=>	MlznV2FPT0WU
A2780	M3XLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTNwNkSwPFkh\|ryP	M{HMbHNCVkeHUh?=
C2BBe1	NGLROVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXDVnZUUUN3ME2zMlY1PDB5IN88US=>	NHfhXHlUSU6JRWK=
SK-MES-1	M{\6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LPSGlEPTB;Mz62OFYyPCEQvF2=	MWrTRW5ITVJ?
PANC-10-05	NGL2SZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPwTWM2OD1\|LkeyNFczKM7:TR?=	NGTuUlBUSU6JRWK=
J-RT3-T3-5	NXr0WWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HWSmlEPTB;Mz63OVQxPiEQvF2=	NYfJb\|dmW0GQR1XS
ES4	M2rLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHwTWM2OD1\|LkiyNlg3KM7:TR?=	M3:1WnNCVkeHUh?=
NCI-H28	NFfDTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zHOWlEPTB;Mz64Nlk3OSEQvF2=	M3XLTHNCVkeHUh?=
NCI-H1155	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTNwOESxOVkh\|ryP	NUXKUI1yW0GQR1XS
KURAMOCHI	M2\FNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moq1TWM2OD1\|Lki2NFU3KM7:TR?=	MoKwV2FPT0WU
NCI-H69	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnsNlNKSzVyPUOuPVAyPzhizszN	NH\mdnZUSU6JRWK=
IST-MES1	M33RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HhdWlEPTB;Mz65OFAzQSEQvF2=	M3[2NnNCVkeHUh?=
NH-12	NGLZOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPNRZVKSzVyPUOuPVQyQDdizszN	MlXMV2FPT0WU
JVM-2	NV3pR2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVe5N4NsUUN3ME2zMlk1PzV{IN88US=>	MVXTRW5ITVJ?
EW-16	NFvRO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLqTWM2OD1\|Lkm1OVc4KM7:TR?=	M3;XOXNCVkeHUh?=
NCI-H441	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDlZWNiUUN3ME2zMlk4ODF2IN88US=>	NGC5bVNUSU6JRWK=
RCC10RGB	M4rNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHvN5hKUUN3ME20MlAyOjR4IN88US=>	Ml:5V2FPT0WU
TCCSUP	M3PrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHsTWM2OD12LkGxNFUh\|ryP	NY\VdXRKW0GQR1XS
HL-60	NHzy[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHUSll3UUN3ME20MlEzOjRzIN88US=>	NH72WIdUSU6JRWK=
EW-11	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrxbZhJUUN3ME20MlE{OjZzIN88US=>	NYmyRWRrW0GQR1XS
KARPAS-299	M3XNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXjem1nUUN3ME20MlMyODF\|IN88US=>	MlrXV2FPT0WU
SNU-C2B	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTRwM{S2PFYh\|ryP	NY\GPJVQW0GQR1XS
LU-139	MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXLbG5KSzVyPUSuN\|czPDdizszN	M2H4e3NCVkeHUh?=
HCC1937	NVX2RW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTRwM{e5PVMh\|ryP	MlPmV2FPT0WU
GR-ST	NIXZdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjRTWM2OD12LkSzNVgh\|ryP	MnTZV2FPT0WU
SK-OV-3	M4fmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTJSYpwUUN3ME20MlQ3ODR{IN88US=>	NIrMWm9USU6JRWK=
A172	NUTsVJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M16xXGlEPTB;ND61OVUzOSEQvF2=	MmeyV2FPT0WU
NB10	NICwZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PtWmlEPTB;ND61PVc5OSEQvF2=	NIq1T3hUSU6JRWK=
P30-OHK	NIjTeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rmfWlEPTB;ND64NVkzQSEQvF2=	MlnJV2FPT0WU
KYSE-520	NHHOUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TZe2lEPTB;ND64PFAyQCEQvF2=	M3yybnNCVkeHUh?=
KNS-62	NVHN[VVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTRwOUC4NFch\|ryP	NFTPV4lUSU6JRWK=
ES1	NEWzbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fYRmlEPTB;ND65OlA{PSEQvF2=	M{H6e3NCVkeHUh?=
KOSC-2	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrsSGdKSzVyPUSuPVk6PTlizszN	NE\4ZVRUSU6JRWK=
TE-9	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\XVoxKSzVyPUWuNFE2OjVizszN	NX2zV\|llW0GQR1XS
NCI-H1838	M2Did2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXiepBKSzVyPUWuNFIxPzZizszN	NYHzbJBxW0GQR1XS
KP-N-YN	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;qcZFGUUN3ME21MlEzPTlzIN88US=>	MUHTRW5ITVJ?
ALL-PO	NUX6c2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\wTWM2OD13LkKyOVg4KM7:TR?=	NVvPSml5W0GQR1XS
NOMO-1	NYn2fnlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTVwMkOxO\|Yh\|ryP	MkjPV2FPT0WU
CGTH-W-1	MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\CbmlEPTB;NT6zPFU5PCEQvF2=	NHL2RYhUSU6JRWK=
ATN-1	NULsWlJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXqbmlqUUN3ME21MlQyOTh2IN88US=>	MmO0V2FPT0WU
AGS	NYmyeXlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrvTWM2OD13LkS5OlE5KM7:TR?=	MoLlV2FPT0WU
SW13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVm0XFZsUUN3ME21MlU{OjZ3IN88US=>	NV;FSodFW0GQR1XS
SW1990	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkGzTWM2OD13Lk[yNlg2KM7:TR?=	NV;K[\|huW0GQR1XS
BFTC-905	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mne0TWM2OD13Lk[1PFc5KM7:TR?=	MXjTRW5ITVJ?
RMG-I	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXDTWM2OD13Lk[1PVQzKM7:TR?=	MmnlV2FPT0WU
HD-MY-Z	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXPO\|NKSzVyPUWuOlg2QDFizszN	MmjYV2FPT0WU
HCC1187	M3vrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYiwXYhRUUN3ME21MlcyODN{IN88US=>	MV3TRW5ITVJ?
HCC2998	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTVwN{G4O\|ch\|ryP	M4nWW3NCVkeHUh?=
RT-112	NXT3bHhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nkU2lEPTB;NT65NFI1PSEQvF2=	MVHTRW5ITVJ?
CAKI-1	NWThbWJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonETWM2OD14LkCwPVg2KM7:TR?=	NUjBNJBKW0GQR1XS
HDLM-2	NF;2cY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljTTWM2OD14LkCxOFg6KM7:TR?=	NYjRWmQ5W0GQR1XS
TE-10	NELa[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXz1[mF{UUN3ME22MlA1QDN\|IN88US=>	NWD4PJRLW0GQR1XS
KE-37	NIflVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUWxPXE2UUN3ME22MlA4OjV6IN88US=>	NXG3c4FmW0GQR1XS
RCM-1	M1;3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7oTWM2OD14LkC3O\|E6KM7:TR?=	MmP4V2FPT0WU
Mewo	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;WNHZsUUN3ME22MlEyPDh5IN88US=>	NXX2fFk3W0GQR1XS
L-428	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTZwMUiwN\|ch\|ryP	NED0UVhUSU6JRWK=
8-MG-BA	M3;tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1L2fmlEPTB;Nj6xPVM4QSEQvF2=	NHixVGlUSU6JRWK=
SK-MEL-28	M17RN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3BTWM2OD14LkKwPVY4KM7:TR?=	NFvi[HhUSU6JRWK=
VA-ES-BJ	M17Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTZwM{C0OlIh\|ryP	M{HwbXNCVkeHUh?=
CAL-120	NVLEfGlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXFPIxbUUN3ME22MlQ2OTZ{IN88US=>	M4jITHNCVkeHUh?=
GAMG	NHX5RmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2K4NGlEPTB;Nj61NFYzKM7:TR?=	MXzTRW5ITVJ?
MSTO-221H	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfSXZRvUUN3ME22MlUyOTdizszN	NVrsSpBIW0GQR1XS
GCT	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1uwOmlEPTB;Nj61N\|M5PyEQvF2=	M1vNUnNCVkeHUh?=
SH-4	NE\CeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPP[lFsUUN3ME22MlU5QDR2IN88US=>	MnLoV2FPT0WU
Calu-3	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2H1[WlEPTB;Nj62OVU3QCEQvF2=	NFiySW5USU6JRWK=
SK-HEP-1	M{izcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTZwN{G3OVMh\|ryP	MWPTRW5ITVJ?
PFSK-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvzSphKSzVyPU[uO\|M1PzhizszN	NHPRbmVUSU6JRWK=
NB12	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LONmlEPTB;Nj63PFQxPCEQvF2=	NF:3b\|hUSU6JRWK=
A388	MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHreY5KSzVyPU[uPFk2OiEQvF2=	MlGxV2FPT0WU
KLE	NVfNeXZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfYbZFKSzVyPU[uPVY2OTZizszN	NH6xZ3VUSU6JRWK=
TE-11	M4TESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{W3OGlEPTB;Nz6wOFk3PyEQvF2=	MoTGV2FPT0WU
NCI-H2405	NUPSNHlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjDdJRKSzVyPUeuNFg{QTNizszN	MnXXV2FPT0WU
OVCAR-4	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\zRmlEPTB;Nz6xOVM2KM7:TR?=	MWfTRW5ITVJ?
KP-N-YS	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7McJdKSzVyPUeuNVgyPCEQvF2=	M3niUHNCVkeHUh?=
NOS-1	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXm3PZNCUUN3ME23MlI2QDJ6IN88US=>	NIW0PGVUSU6JRWK=
DMS-114	NEnERVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWmwe4xGUUN3ME23MlI6PjNzIN88US=>	MkPwV2FPT0WU
NCI-H2030	NETDUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTdwM{O2PVgh\|ryP	NFrRV3NUSU6JRWK=
HEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTdwM{e1NlEh\|ryP	M2P5UXNCVkeHUh?=
CAL-62	NHSzVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17v[2lEPTB;Nz6zPVg3PiEQvF2=	MknwV2FPT0WU
COLO-668	M{fLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzUVFNKSzVyPUeuOFM6PjdizszN	NWn3S\|QzW0GQR1XS
SKG-IIIa	Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1S0eWlEPTB;Nz60OVM5OSEQvF2=	M4nIfXNCVkeHUh?=
HCC1419	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXpR5VGUUN3ME23MlQ3QDN\|IN88US=>	NWPuS216W0GQR1XS
OS-RC-2	M33hR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETCOHpKSzVyPUeuOFk5QTRizszN	NWDq[oFkW0GQR1XS
COLO-829	Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILzbXZKSzVyPUeuOlY1PjNizszN	NVj4cIhtW0GQR1XS
NB13	NGDTV\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTdwOEK2Olch\|ryP	NGLKN\|JUSU6JRWK=
DK-MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vwZmlEPTB;Nz64N\|IxOSEQvF2=	NETzSYdUSU6JRWK=
SHP-77	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTdwOE[2OVMh\|ryP	NYDkXlNWW0GQR1XS
NCI-H661	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LqV2lEPTB;OD6wOVg3PyEQvF2=	MWDTRW5ITVJ?
AM-38	NXj0TVg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUe2UXBCUUN3ME24MlE3OjhizszN	Moq0V2FPT0WU
VM-CUB-1	NIq1SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRThwMUewNlkh\|ryP	MWnTRW5ITVJ?
KYSE-70	NYfOdYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPYTWM2OD16LkG5O\|YyKM7:TR?=	M3HrW3NCVkeHUh?=
5637	M3TyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnlUG5KSzVyPUiuN\|ExPTVizszN	NUPIXWJuW0GQR1XS
TGBC11TKB	NGfTNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLtWWhKSzVyPUiuOFYyPjRizszN	NIDoPGFUSU6JRWK=
EGI-1	NHPOXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPGTWM2OD16Lk[wNFg5KM7:TR?=	NIXNRolUSU6JRWK=
D-392MG	NES5N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD1TWM2OD16Lk[2NlE1KM7:TR?=	NHuwUFlUSU6JRWK=
A673	NI\SPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPzT5ZCUUN3ME24MlY4PjFzIN88US=>	NWDncopzW0GQR1XS
COLO-792	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXsRmpKSzVyPUiuO\|Q6PDZizszN	NIXxbGZUSU6JRWK=
NCI-H1792	NX\MclZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP1TWM2OD16Lki4PVA{KM7:TR?=	NILMfWNUSU6JRWK=
LS-1034	MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fi[mlEPTB;OD65OFY2OiEQvF2=	NYfB[481W0GQR1XS
D-566MG	NFP6XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTlwMEG4NUDPxE1?	MXPTRW5ITVJ?
NCI-H226	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnTZZZ3UUN3ME25MlA6KM7:TR?=	MUfTRW5ITVJ?
ChaGo-K-1	M3vTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTlwMUC1O\|kh\|ryP	NV\GZWlEW0GQR1XS
NCI-H2228	M3HCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PTOWlEPTB;OT6xNVA5OSEQvF2=	NWTRRVFQW0GQR1XS
RPMI-8226	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz3TWM2OD17LkGxN\|A1KM7:TR?=	M1q3fHNCVkeHUh?=
BFTC-909	MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnROm1KSzVyPUmuNVgzQTdizszN	NFzGe3VUSU6JRWK=
HPAF-II	NXrKSnE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTBTWM2OD17LkKyOVE5KM7:TR?=	MkjXV2FPT0WU
Capan-2	M3fTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojsTWM2OD17LkSwNVA6KM7:TR?=	MkH6V2FPT0WU
IA-LM	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTlwNEG5OlYh\|ryP	NVz3[YRxW0GQR1XS
KP-4	NWPvZ2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjWPIxKSzVyPUmuOFg5OzhizszN	NF\qO4pUSU6JRWK=
A101D	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnkWWRSUUN3ME25MlUyPzF7IN88US=>	NXvVepRYW0GQR1XS
EFO-21	NUD6[W9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPJWVJRUUN3ME25MlU5PzN3IN88US=>	MUHTRW5ITVJ?
C32	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrFNHJKSzVyPUmuOlM{PCEQvF2=	M1nrRXNCVkeHUh?=
SW837	NUHQTmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHwelU{UUN3ME25Mlg1QDJizszN	NFj4XXRUSU6JRWK=
OCI-AML2	M4m0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\NTWM2OD17Lki2PVYh\|ryP	MmTrV2FPT0WU
NCI-H1355	NVL5[odyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\se\|JKSzVyPUmuPVQxQDhizszN	NEDWUVRUSU6JRWK=
NCI-H2342	NI\QRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPkTWM2OD1zMD6wNVU2KM7:TR?=	NGriXGZUSU6JRWK=
A204	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3u4[WlEPTB;MUCuNFQ3PiEQvF2=	M3[4c3NCVkeHUh?=
CAL-51	NFfDU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[ySm9KSzVyPUGwMlA5PzdizszN	MYXTRW5ITVJ?
HCE-4	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\0OJY2UUN3ME2xNE4yOTJ{IN88US=>	NU\uS4JIW0GQR1XS
NCI-H810	NVjkTJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEn1fpNKSzVyPUGwMlE2QTdizszN	M174WXNCVkeHUh?=
DJM-1	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFyLkG3N\|Ih\|ryP	MVvTRW5ITVJ?
SK-UT-1	NIHudVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;wXGlEPTB;MUCuNlU4PCEQvF2=	MVvTRW5ITVJ?
U031	NFLwcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfDR4FDUUN3ME2xNE4zPjh4IN88US=>	Mn[wV2FPT0WU
YH-13	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITCSHdKSzVyPUGwMlMxPTdizszN	M173UXNCVkeHUh?=
K5	MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnq1TWM2OD1zMD6zN\|k2KM7:TR?=	M{jKTXNCVkeHUh?=
HEC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXoV5ROUUN3ME2xNE41ODhzIN88US=>	NGe4cIdUSU6JRWK=
A2058	NYTMZZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTWV5NNUUN3ME2xNE42PDlzIN88US=>	M13MPHNCVkeHUh?=
SW962	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoH1TWM2OD1zMD62NlA1KM7:TR?=	MUHTRW5ITVJ?
VMRC-RCZ	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj3S4FKSzVyPUGwMlY4PDlizszN	MmXyV2FPT0WU
D-336MG	NWHET45wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFyLkewNFUh\|ryP	MUHTRW5ITVJ?
LXF-289	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfO[mRqUUN3ME2xNE44QTZ5IN88US=>	MX7TRW5ITVJ?
SW900	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Lpe2lEPTB;MUCuPFIzQCEQvF2=	NWn4WGFHW0GQR1XS
K-562	NVnhRYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\OTWM2OD1zMD64N\|k2KM7:TR?=	NIHYXYtUSU6JRWK=
HCC38	NYfaZ5ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\wZodKSzVyPUGwMlk4OTZizszN	NF:yXotUSU6JRWK=
SF-295	NXnB[2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LLc2lEPTB;MUCuPVkxOiEQvF2=	NXzqbFlqW0GQR1XS
LB831-BLC	M1:2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fMdGlEPTB;MUGuNlU2PiEQvF2=	NEXpR3RUSU6JRWK=
FTC-133	NW\o[29LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTFzLkOwPFEh\|ryP	MUHTRW5ITVJ?
HCC1954	NIjhenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TjUWlEPTB;MUGuOFM3KM7:TR?=	MYHTRW5ITVJ?
GOTO	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFqxcmJKSzVyPUGxMlUzODZizszN	NFL2NpBUSU6JRWK=
LS-411N	M1XFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXOXlNKSzVyPUGxMlYyODFizszN	NI\3XGpUSU6JRWK=
RPMI-7951	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLscnlKSzVyPUGxMlY{PDhizszN	M1\KZXNCVkeHUh?=
NCI-H1299	NVnmb4ttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TXVGlEPTB;MUGuOlY1PyEQvF2=	MkLOV2FPT0WU
MLMA	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjnTWM2OD1zMT62PVk4KM7:TR?=	NWHmVWYzW0GQR1XS
MMAC-SF	M1nu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFzLkeyOVIh\|ryP	MWnTRW5ITVJ?
UM-UC-3	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrFS2tYUUN3ME2xNU44PDJzIN88US=>	MnrPV2FPT0WU
SCC-9	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFzLkixOVEh\|ryP	NXKxZXlLW0GQR1XS
HOS	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzsWW9KSzVyPUGxMlg3QDNizszN	NWT1bmdLW0GQR1XS
OE19	M3Xl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLqTWM2OD1zMT65N\|Y4KM7:TR?=	M3LiTnNCVkeHUh?=
Mo-T	NIP6N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjoWo5KSzVyPUGxMlk2PDFizszN	MV\TRW5ITVJ?
CAMA-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPzZmxKSzVyPUGyMlE3OzNizszN	MVzTRW5ITVJ?
U-118-MG	M2LRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHaTIFKSzVyPUGyMlI1PDFizszN	NHrOU\|BUSU6JRWK=
KS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTF{LkK4N\|Ih\|ryP	NVP5fFNMW0GQR1XS
JAR	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;DZlFKSzVyPUGyMlM{PjlizszN	Mo\SV2FPT0WU
ABC-1	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3NTWM2OD1zMj6zOFEh\|ryP	NGniTldUSU6JRWK=
Daoy	NFvBc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF{LkS1OFIh\|ryP	NGPUemtUSU6JRWK=
C3A	NEmycIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTF{LkW3PFUh\|ryP	NX:xPZdkW0GQR1XS
GT3TKB	M1PtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjGb2ZKSzVyPUGyMlY{OjdizszN	M1LwXHNCVkeHUh?=
DMS-273	NEDyRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknpTWM2OD1zMj64OlM{KM7:TR?=	MV3TRW5ITVJ?
G-361	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULPXoJXUUN3ME2xNk46OTJ7IN88US=>	NWPSVGJTW0GQR1XS
RH-18	NUTBO2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTF\|LkK5OlIh\|ryP	NY\RbIw4W0GQR1XS
SN12C	M2TKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF\|LkO4NFgh\|ryP	M3PoVHNCVkeHUh?=
NCI-H1993	M{n3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTF\|LkSyPFUh\|ryP	MWXTRW5ITVJ?
LOXIMVI	MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTPTWM2OD1zMz62NVUyKM7:TR?=	MULTRW5ITVJ?
SK-PN-DW	NYX4W2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDkcZNKSzVyPUGzMlg1OjdizszN	NGXDOpdUSU6JRWK=
KALS-1	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTZTWM2OD1zMz64OVI2KM7:TR?=	MoDiV2FPT0WU
LAN-6	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PvS2lEPTB;MUSuNlU{KM7:TR?=	MnHjV2FPT0WU
A549	Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD0TWM2OD1zND60O\|EzKM7:TR?=	M172cHNCVkeHUh?=
RD	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL1TWM2OD1zND60PFE{KM7:TR?=	MmLrV2FPT0WU
TGBC1TKB	M2PJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF2Lk[2NVUh\|ryP	M33SXHNCVkeHUh?=
NCI-H630	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnj5TWM2OD1zND65OFY4KM7:TR?=	NGrIUGdUSU6JRWK=
MIA-PaCa-2	NIrYTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjKUm1KSzVyPUG0Mlk3QSEQvF2=	MlPhV2FPT0WU
NCI-H1755	M3LQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTF2Lkm5OVMh\|ryP	MVPTRW5ITVJ?
MOLT-4	NHrTS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HJXGlEPTB;MUWuNFQ6PyEQvF2=	MVXTRW5ITVJ?
CW-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTF3LkG0NlEh\|ryP	M2HST3NCVkeHUh?=
COLO-320-HSR	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfle\|ZZUUN3ME2xOU42OzB5IN88US=>	NHr3fWVUSU6JRWK=
UMC-11	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlexTWM2OD1zNT63OVI{KM7:TR?=	M2j2PXNCVkeHUh?=
MCF7	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGCxW25KSzVyPUG1MlgyPDVizszN	NV\O[nZvW0GQR1XS
NCI-H23	NXexV2dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfQdW5KSzVyPUG1Mlg1OzhizszN	NUfYS\|V{W0GQR1XS
HuCCT1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfSTWM2OD1zNT64O\|Qh\|ryP	MVPTRW5ITVJ?
MPP-89	M1PseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17icmlEPTB;MUWuPVQyPyEQvF2=	NI\5fpFUSU6JRWK=
HT55	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW3NoxnUUN3ME2xOU46PDd6IN88US=>	MXvTRW5ITVJ?
no-11	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PIUGlEPTB;MUWuPVY3OyEQvF2=	NYfsNnFoW0GQR1XS
GP5d	M33mOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF4LkKxPFch\|ryP	NVjweFBRW0GQR1XS
BHT-101	NVLmWZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXPXW1KSzVyPUG2MlI1OzlizszN	NUPySWJZW0GQR1XS
M059J	M{\YOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;P[mtMUUN3ME2xOk4zQDRizszN	M1X1bHNCVkeHUh?=
D-283MED	MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LiOWlEPTB;MU[uOFIxQSEQvF2=	MkThV2FPT0WU
BEN	M2jrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkexTWM2OD1zNj61NVU2KM7:TR?=	M4mzPHNCVkeHUh?=
LB373-MEL-D	M1n0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PIXWlEPTB;MU[uO\|I{OiEQvF2=	NXPxc\|FbW0GQR1XS
MEL-HO	NGfpOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXQZVJHUUN3ME2xOk45QDV2IN88US=>	MlzZV2FPT0WU
GI-ME-N	NIHjZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTiZYdNUUN3ME2xOk46ODN{IN88US=>	NFvnW41USU6JRWK=
RKO	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Lsc2lEPTB;MUeuNFc1QCEQvF2=	Mk\LV2FPT0WU
MZ2-MEL	M{e3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTF5LkGzN{DPxE1?	NEfjNYRUSU6JRWK=
NCI-H1573	NVPESmRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTF5LkK4NlYh\|ryP	Mn;KV2FPT0WU
NCI-H1581	NFvje3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknyTWM2OD1zNz60OFEyKM7:TR?=	NVXmbo9oW0GQR1XS
NCI-H747	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LqemlEPTB;MUeuOVI6PyEQvF2=	MUfTRW5ITVJ?
SW1783	NET5XGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\4RXhDUUN3ME2xO{43PDF3IN88US=>	NHvXRYdUSU6JRWK=
Calu-6	M2Kwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2f2OmlEPTB;MUeuOlc5OiEQvF2=	NESxUXdUSU6JRWK=
SF268	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\6e5FKUUN3ME2xO{43QTZ7IN88US=>	NVPDcXVqW0GQR1XS
ES8	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTF5Lki1PVMh\|ryP	MVrTRW5ITVJ?
KM-H2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LYW2lEPTB;MUeuPVQyOSEQvF2=	MlXoV2FPT0WU
D-502MG	NE\U[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXDTWM2OD1zNz65PFA5KM7:TR?=	MV7TRW5ITVJ?
HLE	NWPsZ5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzZOYpKSzVyPUG4MlMyPDhizszN	MUfTRW5ITVJ?
SW982	NUjLUId[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHVZ\|R{UUN3ME2xPE41ODd3IN88US=>	M3r4PXNCVkeHUh?=
MDA-MB-361	M4HJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULBV5h{UUN3ME2xPE42PTh6IN88US=>	MXHTRW5ITVJ?
NCI-H1563	NX7U[WMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkf1TWM2OD1zOD63NVI1KM7:TR?=	NGHEbmhUSU6JRWK=
MFE-280	M37tNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF6LkeyPVMh\|ryP	NH7MZpdUSU6JRWK=
U251	NIfGVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILBVllKSzVyPUG4Mlc{PDdizszN	MXvTRW5ITVJ?
KNS-42	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTSSnRIUUN3ME2xPE45ODF3IN88US=>	M2HQ[HNCVkeHUh?=
U-266	NIjDeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHz0b3NKSzVyPUG4Mlg3PDlizszN	NXLsZWI6W0GQR1XS
OVCAR-8	M3e1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF6LkmyO\|Yh\|ryP	NHXFS25USU6JRWK=
MFH-ino	NES0V4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3frcGlEPTB;MUiuPVY3QSEQvF2=	M3XOZnNCVkeHUh?=
D-263MG	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzH[WtDUUN3ME2xPU4xOTd{IN88US=>	NHrkcYhUSU6JRWK=
NCI-H1437	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3uxOGlEPTB;MUmuNFQ3PyEQvF2=	MVzTRW5ITVJ?
NCI-H1048	NXTN[JpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTF7LkKzNlYh\|ryP	M3O4THNCVkeHUh?=
NCI-H446	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPrTWM2OD1zOT6zOVg6KM7:TR?=	MnnDV2FPT0WU
NCI-N87	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTF7LkW5PVIh\|ryP	NUjnR\|RvW0GQR1XS
WM-115	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfYNJg{UUN3ME2xPU43Pzd2IN88US=>	Ml3zV2FPT0WU
HuH-7	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvVWoQyUUN3ME2xPU44PDJzIN88US=>	NF[0dXVUSU6JRWK=
NCI-H650	NU\XSIluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF7Lke1NFgh\|ryP	MWPTRW5ITVJ?
TYK-nu	M2TDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDTTWM2OD1zOT64N\|c5KM7:TR?=	MWPTRW5ITVJ?
Becker	NIXaelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jROGlEPTB;MUmuPFU1PyEQvF2=	NXnJO\|QxW0GQR1XS
BB49-HNC	M1vCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\xZWxvUUN3ME2xPU46OiEQvF2=	NYe4XGo6W0GQR1XS
HGC-27	M4rQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJyLkGzPVQh\|ryP	NV;CTmdCW0GQR1XS
SiHa	M1PWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTJyLkO3NVIh\|ryP	NFzDdFdUSU6JRWK=
LB2518-MEL	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJyLkO3N\|kh\|ryP	M{PiR3NCVkeHUh?=
TE-5	NX\GSZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\wVWVKSzVyPUKwMlc1QDJizszN	NFzEeYhUSU6JRWK=
IST-SL1	MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoW4TWM2OD1{MD63PFc6KM7:TR?=	NI\lUnhUSU6JRWK=
A375	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPKTWM2OD1{MT6wOVY4KM7:TR?=	NUT5UpZJW0GQR1XS
MC116	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXtTWM2OD1{MT6wO\|I{KM7:TR?=	MUTTRW5ITVJ?
GI-1	M3XHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTJzLkG3JO69VQ>?	NXX6bJlNW0GQR1XS
HOP-62	NW\XTlR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\XS5pKSzVyPUKxMlI4QDRizszN	NIDQcGFUSU6JRWK=
PA-1	NHmweVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPjSYRKSzVyPUKxMlI4QDdizszN	NVfXNoE4W0GQR1XS
HT	NVq2Smc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nIdmlEPTB;MkGuOFM{OSEQvF2=	MUfTRW5ITVJ?
HUTU-80	NWDEd4dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;YTWM2OD1{MT60N\|M3KM7:TR?=	NF3NRm1USU6JRWK=
NCI-H1975	NYjycG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3oTWM2OD1{MT60OlEh\|ryP	NX7V[nJtW0GQR1XS
GAK	NYPsSlVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnxXlB[UUN3ME2yNU41QTlizszN	MlPPV2FPT0WU
SK-N-AS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\4PHRJUUN3ME2yNU42PjF7IN88US=>	NX3DOVk{W0GQR1XS
OE33	NX3IVG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzwcnFKSzVyPUKxMlYxPDZizszN	M4LLNHNCVkeHUh?=
YKG-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rTVGlEPTB;MkGuOlU1PSEQvF2=	NWTHSopJW0GQR1XS
CAL-85	NYnUeZQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK4TWM2OD1{MT65N\|A2KM7:TR?=	NV\JOJFWW0GQR1XS
NCI-H2347	MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ryUmlEPTB;MkGuPVQzQCEQvF2=	M3K2[3NCVkeHUh?=
PANC-08-13	MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXGWG55UUN3ME2yNk4xOTF7IN88US=>	NGPGVXFUSU6JRWK=
SK-N-FI	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPjdopKSzVyPUKyMlMxPzRizszN	MmC5V2FPT0WU
NEC8	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TK[WlEPTB;MkKuOVA4QCEQvF2=	MmDsV2FPT0WU
AN3-CA	M1XsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2H4NmlEPTB;MkKuOlA5PCEQvF2=	NY\J[5pMW0GQR1XS
HuO9	M2HwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkP0TWM2OD1{Mj63N\|k3KM7:TR?=	MlHJV2FPT0WU
COLO-800	MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3aR3JKSzVyPUKyMlc3PTNizszN	NWfOVld1W0GQR1XS
HT-29	NXj6O3RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPSTWM2OD1{Mj64PFI{KM7:TR?=	NWf3Rod3W0GQR1XS
OC-314	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULJUoFiUUN3ME2yNk45QDR3IN88US=>	Mk\oV2FPT0WU
G-401	NEHBRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nvPWlEPTB;MkOuNFQ3OiEQvF2=	NITlOpdUSU6JRWK=
Saos-2	NGD4cJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DG[2lEPTB;MkOuOVE5OiEQvF2=	NFjXNm1USU6JRWK=
UACC-62	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJ\|LkW4N\|Mh\|ryP	MlXPV2FPT0WU
D-247MG	NH[yS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXNPVBLUUN3ME2yN{44QTN7IN88US=>	MoXIV2FPT0WU
COLO-741	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTJTWM2OD1{Mz65OVY2KM7:TR?=	MWDTRW5ITVJ?
ES3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4iwcGlEPTB;MkSuNFAzOyEQvF2=	NHzNdIJUSU6JRWK=
LNCaP-Clone-FGC	NGDTRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvzcVNRUUN3ME2yOE4xOjFzIN88US=>	M4LBPHNCVkeHUh?=
SW1710	NVm0eZFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\vOmlEPTB;MkSuNVUxPiEQvF2=	MUjTRW5ITVJ?
LU-99A	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnj5TWM2OD1{ND6xPFQyKM7:TR?=	M2H0[XNCVkeHUh?=
HOP-92	NXfzfW83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nYTmlEPTB;MkSuO\|I2KM7:TR?=	MmPTV2FPT0WU
LS-123	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJ2Lkm2NVQh\|ryP	M{LUdnNCVkeHUh?=
T84	NIfHZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PseWlEPTB;MkSuPVc3PSEQvF2=	NGeyPHBUSU6JRWK=
HCT-116	MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TTUGlEPTB;MkWuOFE5PiEQvF2=	MYLTRW5ITVJ?
M14	MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJ3LkS0OFch\|ryP	M3fOVHNCVkeHUh?=
OCUB-M	NH3LUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;ZO2hkUUN3ME2yOU41PDV4IN88US=>	NH71e4ZUSU6JRWK=
MKN45	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHQTWM2OD1{NT62N\|E2KM7:TR?=	MY\TRW5ITVJ?
LCLC-97TM1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHuXnFEUUN3ME2yOU44Ojh3IN88US=>	NGLBWIlUSU6JRWK=
RVH-421	NYXRVGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LDdmlEPTB;MkWuPFE3OSEQvF2=	MWDTRW5ITVJ?
NKS-81-FD	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\PPGlEPTB;MkWuPVAzOSEQvF2=	MVLTRW5ITVJ?
NCI-H596	MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vBbGlEPTB;Mk[uNFQ5PyEQvF2=	NETU[4NUSU6JRWK=
GB-1	NFu5fo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHyTWM2OD1{Nj6xPFc6KM7:TR?=	NX7udZh[W0GQR1XS
ZR-75-30	NUDUNllUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy0Z5hKSzVyPUK2MlIzQTdizszN	NYDSR2l2W0GQR1XS
U-2-OS	NHjGclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\5S2lEPTB;Mk[uN\|c2PyEQvF2=	NEj1bJpUSU6JRWK=
HuP-T3	MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LLRmlEPTB;Mk[uOlExOiEQvF2=	NV3hcFJjW0GQR1XS
MOLT-16	M3LhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHO5dVBKSzVyPUK2MlYyPjZizszN	M2HVcHNCVkeHUh?=
U-87-MG	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DafGlEPTB;Mk[uO\|Q{QCEQvF2=	NVj2fGhyW0GQR1XS
8505C	MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXQTWM2OD1{Nj65NVI3KM7:TR?=	MnrtV2FPT0WU
SK-MEL-3	NFf6e4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLtOlV4UUN3ME2yOk46QDJ6IN88US=>	M4CxSHNCVkeHUh?=
COLO-824	NGTLfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoOyTWM2OD1{Nz6yNVk2KM7:TR?=	NEnZdI1USU6JRWK=
EW-1	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWi0RWl7UUN3ME2yO{4{PTV2IN88US=>	MlvBV2FPT0WU
UACC-257	NXzVSJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:0UoJSUUN3ME2yO{4{QDB2IN88US=>	NEmwXGRUSU6JRWK=
Hs-578-T	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTJ5LkWyPVkh\|ryP	NHz1eWhUSU6JRWK=
UACC-893	M13nZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\tXHlKSzVyPUK3MlY3OzFizszN	NFfWRolUSU6JRWK=
MHH-NB-11	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjDbY1KSzVyPUK3MlgxODdizszN	NU\IdXE{W0GQR1XS
KYSE-410	M1XOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HMc2lEPTB;MkiuNlc4QSEQvF2=	NVjiNZlHW0GQR1XS
SF126	Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJ6Lke0N\|Uh\|ryP	NI[xVmxUSU6JRWK=
HT-144	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYe0bnFmUUN3ME2yPU4{OzZ{IN88US=>	MWjTRW5ITVJ?
SW1573	NXPYdGM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlG4TWM2OD1{OT6zOVA6KM7:TR?=	NYLZXZFYW0GQR1XS
SW620	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJ7LkO2OFEh\|ryP	NXu5fVh{W0GQR1XS
SCH	NUTVOmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWr6VYNLUUN3ME2yPU45QDNzIN88US=>	NHLRNZRUSU6JRWK=
EW-22	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYqyV\|c1UUN3ME2zNE4yQTZ7IN88US=>	NXj3UJVGW0GQR1XS
H4	NGjJfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;1SmlEPTB;M{CuOFY2PCEQvF2=	MkLUV2FPT0WU
CAS-1	NXjnWIVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTNyLke4OVkh\|ryP	M3TLfnNCVkeHUh?=
MG-63	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXWUWlJUUN3ME2zNE45PDd6IN88US=>	MVrTRW5ITVJ?
MDA-MB-415	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTNzLkG3OVMh\|ryP	M3j1fHNCVkeHUh?=
NCI-H1395	NYPJSpZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTNzLkKzNlgh\|ryP	NGjFcIpUSU6JRWK=
Ca-Ski	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nmdmlEPTB;M{GuN\|E4PyEQvF2=	MVXTRW5ITVJ?
BxPC-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnXfohkUUN3ME2zNU4{PzJ7IN88US=>	M2TETHNCVkeHUh?=
A3-KAW	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPOSnNKSzVyPUOxMlQ1PzFizszN	NIL1[GJUSU6JRWK=
T-24	M3\EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DaUmlEPTB;M{GuO\|M3OiEQvF2=	M3LMeHNCVkeHUh?=
NCI-H2029	NVvTZnV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\0[2c3UUN3ME2zNU44PzZ3IN88US=>	M3f5O3NCVkeHUh?=
YAPC	M1PKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInUfnVKSzVyPUOyMlA1ODdizszN	M3HQNHNCVkeHUh?=
SK-MEL-2	M33YNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTN{LkC1NkDPxE1?	MV;TRW5ITVJ?
LS-513	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfXTWM2OD1\|Mj6xNVg4KM7:TR?=	M335O3NCVkeHUh?=
AsPC-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTN{LkO2NFUh\|ryP	NUPxNVhtW0GQR1XS
KYSE-150	NXvuc\|lWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnNdI1UUUN3ME2zNk4{Pzd\|IN88US=>	MUPTRW5ITVJ?
NCI-H520	Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DRUmlEPTB;M{KuOFQ5OiEQvF2=	NWLuUZk1W0GQR1XS
JEG-3	M12zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknSTWM2OD1\|Mz6wPVcyKM7:TR?=	NVzTdWtWW0GQR1XS
GMS-10	NWTteHhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{ixe2lEPTB;M{OuN\|AxPCEQvF2=	NF[yPYJUSU6JRWK=
HT-1080	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTN\|LkO5JO69VQ>?	MV3TRW5ITVJ?
NCI-H1651	NVnhXml[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjueVJKSzVyPUOzMlM6PiEQvF2=	MnfKV2FPT0WU
NCI-H2122	NYrBVlFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rINmlEPTB;M{OuOVU4PCEQvF2=	MYfTRW5ITVJ?
ES5	M2LXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmeyTWM2OD1\|Mz63NlkzKM7:TR?=	MkXMV2FPT0WU
8305C	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvteoVKSzVyPUOzMlk6OzdizszN	MXjTRW5ITVJ?
KM12	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTN2LkC0O\|gh\|ryP	NFTK[nJUSU6JRWK=
HCT-15	NV;PbmZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmS0TWM2OD1\|ND6xNlch\|ryP	NHHQeW9USU6JRWK=
OVCAR-5	NVn2UVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTxRndKSzVyPUO0MlIyQDJizszN	M{P5NXNCVkeHUh?=
NCI-H2291	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXoTWM2OD1\|ND6yOFczKM7:TR?=	MWrTRW5ITVJ?
CP50-MEL-B	NX:5SlVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fhSWlEPTB;M{SuOlU6OiEQvF2=	MUjTRW5ITVJ?
C-33-A	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVG5TndkUUN3ME2zOE43QDV5IN88US=>	M4jzVnNCVkeHUh?=
NCI-H2452	M4SzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS4TWM2OD1\|ND63PFgzKM7:TR?=	MV7TRW5ITVJ?
MDA-MB-157	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\I[VBlUUN3ME2zOE45OTl\|IN88US=>	M1XEfnNCVkeHUh?=
LN-405	M1HvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fuZmlEPTB;M{WuOFMxQCEQvF2=	MWXTRW5ITVJ?
MDA-MB-231	M1rSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTN3LkWwOVQh\|ryP	M2PIbXNCVkeHUh?=
EW-24	M37Zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVK3OY4{UUN3ME2zOU43OzN3IN88US=>	M{D2c3NCVkeHUh?=
MKN28	NIf0SG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\s[FNKSzVyPUO1MlgzOzZizszN	NYXmSJlbW0GQR1XS
KINGS-1	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[5SWlEPTB;M{WuPFQ{PCEQvF2=	MlzBV2FPT0WU
LC-2-ad	M2TpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTN4Lk[5PUDPxE1?	MmLpV2FPT0WU
IGR-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M333emlEPTB;M{[uO\|A4PSEQvF2=	NETUW5BUSU6JRWK=
SW626	NFXWOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XjV2lEPTB;M{euNFQyPyEQvF2=	MVfTRW5ITVJ?
ONS-76	NE\EbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTN5LkGzNFkh\|ryP	NITKNYFUSU6JRWK=
T98G	NUnmeZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTN5Lki2N\|Uh\|ryP	MUfTRW5ITVJ?
NB14	M1;TUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknWTWM2OD1\|OD60OVQ1KM7:TR?=	M3P1WnNCVkeHUh?=
D-423MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTN6LkS4Olkh\|ryP	NGTRfFlUSU6JRWK=
NCI-H510A	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPU[4dTUUN3ME2zPE43PDVzIN88US=>	M3:wXnNCVkeHUh?=
NMC-G1	NI\DU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHvTWM2OD1\|OD63NlIzKM7:TR?=	M{XGRXNCVkeHUh?=
SW948	NYKwOnN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTN6Lki5OFkh\|ryP	NHvaN3dUSU6JRWK=
MFM-223	NWPES2FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTN6Lkm0N\|Eh\|ryP	M2S4VnNCVkeHUh?=
PAN1	NUPDfWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHhZYdKSzVyPUO4Mlk6OTlizszN	NVe2PGZkW0GQR1XS
MZ7-mel	M3i5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrodWtKSzVyPUO5MlEyQTlizszN	MYLTRW5ITVJ?
COLO-679	NWXDOY1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPPenpyUUN3ME2zPU46PzB6IN88US=>	NXSyWGVbW0GQR1XS
SW872	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXy0Zm9SUUN3ME20NE4zODNzIN88US=>	MXLTRW5ITVJ?
HT-1197	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LLXmlEPTB;NECuNlg3QSEQvF2=	M4nPcnNCVkeHUh?=
ES6	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLuW2lvUUN3ME20NE41PTV{IN88US=>	M1f0bHNCVkeHUh?=
SNU-387	NWrNOpJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjMTWM2OD12MD64NlM5KM7:TR?=	NYLkZVRWW0GQR1XS
T47D	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;KTWM2OD12MT6wNVkzKM7:TR?=	MYXTRW5ITVJ?
G-402	NEOzdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\5copxUUN3ME20NU4xQDB7IN88US=>	MojhV2FPT0WU
MZ1-PC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLtTWM2OD12MT64NUDPxE1?	NYnGWnhSW0GQR1XS
SW1417	NXv0WJB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTR{LkOwN{DPxE1?	MWjTRW5ITVJ?
RERF-LC-MS	NYT3[HhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVS5ZWxYUUN3ME20Nk42ODh5IN88US=>	M1XBdHNCVkeHUh?=
SF539	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHzZnRKSzVyPUSyMlU2OjlizszN	MWLTRW5ITVJ?
ESS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH23OXBKSzVyPUSzMlU2PThizszN	MoT1V2FPT0WU
RO82-W-1	M{Xn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXzTWM2OD12Mz62NVU{KM7:TR?=	MmXGV2FPT0WU
S-117	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{f4SmlEPTB;NEOuOlk2QCEQvF2=	NFvCTnVUSU6JRWK=
SW756	M2XZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTR\|LkiyOFIh\|ryP	MVfTRW5ITVJ?
CP66-MEL	MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TQeWlEPTB;NEWuO\|E1OyEQvF2=	M1XLVXNCVkeHUh?=
H-EMC-SS	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3P0c2lEPTB;NEWuO\|Y6OyEQvF2=	MUXTRW5ITVJ?
NCI-H2052	NUjuXnhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTuXm9KSzVyPUS1MlkxOjdizszN	MXXTRW5ITVJ?
SW684	M3XqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTR5LkCwPFEh\|ryP	NY\obYgzW0GQR1XS
HCC1569	MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV72XXoyUUN3ME20O{4yPjV6IN88US=>	MYfTRW5ITVJ?
KGN	NGq0VWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTRTWM2OD12Nz6zN\|EyKM7:TR?=	MXPTRW5ITVJ?
LCLC-103H	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\PN2lEPTB;NEeuOFQxPCEQvF2=	M4j5fXNCVkeHUh?=
SW780	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTR5Lk[zOVEh\|ryP	M2PHPXNCVkeHUh?=
NCI-H1703	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUiwdJNDUUN3ME20PE4{OzV{IN88US=>	NHvYWGtUSU6JRWK=
HCC1395	M2LnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTR6Lke0N\|Ih\|ryP	NGLZTpdUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

体内研究

Gefitinib 作用于无胸腺裸鼠，抑制SKOV3 或MDA-MB-231 肿瘤生长。Gefitinib高效作用于两种类型肿瘤。处理14天后，MDA-MB-231肿瘤和SKOV3肿瘤生长抑制分别为71%和32%。

细胞实验：^[1]	+ 展开 Cell lines: NR6, NR6M 和 NR6W 细胞 Concentrations: 0 μM -2 μM Incubation Time: 72 小时 Method: 呈指数生长的细胞，包括 NR6, NR6M, NR6M和NR6W细胞按6倍接种在96孔板上，每孔为2000个细胞, 粘附，随后在PBS 中清洗，然后在含0.5% FCS的培养基上温育过夜。使用不同浓度(0-2 μM) Gefitinib或溶质对照DMSO 和EGF 处理细胞。诱导NR6wtEGFR和NR6W 细胞增殖的EGF最佳浓度已经测定，因此NR6wtEGFR和 NR6W 细胞中分别加入10 nM和 0.1 nM EGF。NR6 和NR6M细胞中不加入EGF。72 小时后，通过MTT 增殖检测测量细胞数。 (Only for Reference)
动物实验：^[3]	+ 展开 Animal Models: 携带 SKOV3或MDA-MB-231肿瘤的无胸腺裸鼠 Formulation: 0.2% DMSO Dosages: 75 mg/kg Administration: 饲喂处理 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Gefitinib (ZD1839) SDF

分子量	446.90
化学式	C₂₂H₂₄ClFN₄O₃
CAS号	184475-35-2
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03766490	Not yet recruiting	Non-Small-Cell Lung	The First Affiliated Hospital of Soochow University\|The First People''s Hospital of Changzhou\|Second Affiliated Hospital of Soochow University\|Nantong University\|Affiliated Hospital of Jiangnan University\|Jiangyin People''s Hospital\|Changzhou No.2 People''s Hospital\|Chia Tai Tianqing Pharmaceutical Group Co. Ltd.	March 30 2019	Not Applicable
NCT03856697	Not yet recruiting	Advanced Non-small Cell Lung Cancer	Hangzhou ACEA Pharmaceutical Research Co. Ltd.\|Guangdong Provincial People''s Hospital	March 2019	Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
回答：
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

泛EGFR抑制剂

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
活性最高的EGFR抑制剂

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA批准的EGFR抑制剂

Lapatinib : Approved by FDA for breast cancer.
最新的EGFR抑制剂

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

研究领域

产品类型

Gefitinib (ZD1839)

客户使用Selleck该产品发表文献121篇：

产品安全说明书

EGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Gefitinib (ZD1839) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

常见问题及建议解决方法

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

相关EGFR产品